About Prime Medicine
Prime Medicine is a publicly traded biotechnology company (Nasdaq: PRME) founded in 2019 to develop genetic therapies using Prime Editing, a next-generation gene editing technology that performs precise "search and replace" operations on DNA without causing double-strand breaks. The company targets a wide spectrum of genetic diseases, including Wilson Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis, with the goal of providing lifelong cures to patients.
Company details
Funding
Total raised
$490M
Last stage
Public
Investors
Founders
David R. Liu
Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad Institute of MIT and Harvard. Pioneer of Prime Editing and Base Editing technologies. Co-founder of multiple biotech companies including Beam Therapeutics and Editas Medicine.
Keith Gottesdiener
MD. Biotech veteran who led Prime Medicine as President and CEO from founding. Previously helmed Rhythm Pharmaceuticals.
LinkedIn
Andrew Anzalone
MD, PhD. Co-developed Prime Editing technology at the Broad Institute of MIT and Harvard. Joined Prime Medicine as Chief Scientific Officer.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.